Hot Debate: Complement Inhibition vs Nefecon in IgA Nephropathy – Which First for Patients at Risk?

30 Mar 2026 2:10 p.m. 3:10 p.m.

501 - 502

Time	Session

2:10 p.m. 3:10 p.m.	Complement Inhibition Should Be Considered Before Nefecon in Patients With IgAN at Risk of Progression VladoPerkovic Speaker vlado.perkovic@unsw.edu.auAustralia	Nefecon Should Be Considered Before Complement Inhibition in Patients With IgAN at Risk of Progression HongZhang Speaker hongzh@bjmu.edu.cnChina